VIVUS, Inc. Logo

Print Print page   Email Email page   PDF Download PDF    Add to Briefcase
« Previous Release | Next Release »



VIVUS To Present at Four Upcoming Investor Conferences

MOUNTAIN VIEW, Calif., May 10, 2010 /PRNewswire via COMTEX News Network/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that VIVUS management will present an overview of the company at four investment conferences during the month of May.



    The conference presentation schedule is as follows:

    The Ninth Annual JMP Securities Research Conference
    Presented by: Timothy Morris, chief financial officer
    May 11, 2010 at 3:30 p.m. PDT
    Ritz Carlton, San Francisco, CA

    Bank of America Merrill Lynch Health Care Conference
    Presented by: Timothy Morris, chief financial officer
    May 13, 2010 at 10:00 a.m. EDT
    The Grand Hyatt, New York, NY

    Rodman & Renshaw 6th Annual Global Healthcare Conference
    Presented by: Barbara Troupin, M.D., senior director medical affairs
    May 18, 2010 at 3:15 p.m. BST
    Grosvenor House Hotel, London, UK

    2010 Citi Investment Research Global Health Care Conference
    Presented by: Timothy Morris, chief financial officer
    May 26, 2010 at 1:30 p.m. EDT
    Grand Hyatt, New York, NY


A live audio webcast and 30-day archive of the presentations will be available at http://ir.vivus.com.

About VIVUS

VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health. The company's lead product in clinical development, Qnexa(R), has completed phase 3 clinical trials for the treatment of obesity and an NDA has been filed and accepted by the FDA, with an action date of October 28, 2010. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a potentially best-in-class PDE5 inhibitor for the treatment of erectile dysfunction. MUSE(R) (alprostadil), a first generation therapy for the treatment of erectile dysfunction, is already on the market and generating revenue for VIVUS. For more information about the company, please visit www.vivus.com.



    CONTACT:
    --------

    VIVUS, Inc.             Investor Relations: The Trout Group
    Timothy E. Morris                           Brian Korb
    Chief Financial Officer                     646-378-2923
    650-934-5200
                                                 Pure Communications,
                            Media Relations:     Inc.
                                                Dan Budwick
                                                973-271-6085



SOURCE VIVUS, Inc.

Copyright (C) 2010 PR Newswire. All rights reserved

Close window | Back to top